about
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsBiosimilars for the treatment of psoriatic arthritisRemission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot studyTherapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical DataSystematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabrizio Cantini
@ast
Fabrizio Cantini
@en
Fabrizio Cantini
@es
Fabrizio Cantini
@nl
type
label
Fabrizio Cantini
@ast
Fabrizio Cantini
@en
Fabrizio Cantini
@es
Fabrizio Cantini
@nl
prefLabel
Fabrizio Cantini
@ast
Fabrizio Cantini
@en
Fabrizio Cantini
@es
Fabrizio Cantini
@nl
P106
P31
P496
0000-0002-7066-043X